|
注册号: Registration number: |
ChiCTR2500112133 |
|
最近更新日期: Date of Last Refreshed on: |
2025-11-10 18:29:21 |
|
注册时间: Date of Registration: |
2025-11-10 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于VR技术的PCI 术后患者运动恐惧分级暴露干预方案的构建及应用研究 |
|
Public title: |
Construction and application research of a motion fear grading exposure intervention program for post-PCI patients based on VR technology |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于VR技术的PCI 术后患者运动恐惧分级暴露干预方案的构建及应用研究 |
|
Scientific title: |
Construction and application research of a motion fear grading exposure intervention program for post-PCI patients based on VR technology |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吕传武 |
研究负责人: |
王丽娜 |
|
Applicant: |
Chuanwu Lv |
Study leader: |
Lina Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 373 302 9990 |
研究负责人电话:
Study leader's |
+86 373 302 9990 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
1773892742@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
18568566968@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省新乡市红旗区金穗大道601号 |
研究负责人通讯地址: |
河南省新乡市红旗区金穗大道601号 |
|
Applicant address: |
No. 601, Jinshui Avenue, Hongqi District, Xinxiang City, Henan Province |
Study leader's address: |
No. 601, Jinshui Avenue, Hongqi District, Xinxiang City, Henan Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
新乡医学院 |
||
|
Applicant's institution: |
Xinxiang Medical University |
||
|
研究负责人所在单位: |
新乡医学院 |
||
|
Affiliation of the Leader: |
Xinxiang Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
XYLL-20250480 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
新乡医学院伦理委员会 |
||
|
Name of the ethic committee: |
Xinxiang Medical University Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-10-23 00:00:00 | ||
|
伦理委员会联系人: |
张业宏 |
||
|
Contact Name of the ethic committee: |
Yehong Zhang |
||
|
伦理委员会联系地址: |
河南省新乡市红旗区金穗大道601号 |
||
|
Contact Address of the ethic committee: |
No. 601, Jinshui Avenue, Hongqi District, Xinxiang City, Henan Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 373 383 1859 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
新乡医学院 |
||||||||||||||||||||||
|
Primary sponsor: |
Xinxiang Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
河南省新乡市红旗区金穗大道601号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 601, Jinshui Avenue, Hongqi District, Xinxiang City, Henan Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹经费 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self-funded |
||||||||||||||||||||||
|
研究疾病: |
冠心病 |
||||||||||||||||||||||
|
Target disease: |
Coronary heart disease |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.制定针对PCI术后患者运动恐惧的VR技术干预方案。 2.实施干预方案,验证VR技术降低PCI术后患者运动恐惧水平的效果。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Develop a VR technology intervention plan for patients' fear of movement after PCI. 2. Implement the intervention plan to verify the effect of VR technology in reducing the level of motor fear in patients after PCI. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.当前正在参与其他课题研究的患者; 2.对VR不耐受者; 3.存合并其他类型心脏病(如瓣膜病、先天性心脏病、心肌病)或患有恶性肿瘤的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients who are currently participating in other research projects; 2. People who are intolerant to VR; 3. Patients with other types of heart diseases (such as valvular heart disease, congenital heart disease, cardiomyopathy) or those with malignant tumors. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-09-01 00:00:00至 To 2028-08-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-11-15 00:00:00 至 To 2028-08-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
根据随机数字表法进行随机 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Randomization is carried out according to the random number table method |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |